L Mitchell1, D H Thamm, B J Biller. 1. Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523-1620, USA.
Abstract
BACKGROUND: Tyrosine kinase inhibitors (TKIs) and metronomic dosing of cyclophosphamide (CYC) can improve tumor control by suppression of regulatory T cells (Treg) and restoration of T cell-mediated immune responses in mice and humans. The immunomodulatory effects of the TKI toceranib, as a single agent or in combination with metronomic CYC, have not been previously investigated in dogs. HYPOTHESIS: The primary objectives of this study were to determine the effects of toceranib and metronomic CYC treatment on lymphocyte subsets including Treg and on interferon-gamma (IFN-γ) secretion in dogs with cancer. We hypothesized that toceranib would selectively decrease Treg numbers and increase IFN-γ production and that addition of CYC would further enhance these effects. ANIMALS: Fifteen client-owned dogs with advanced tumors were entered into a prospective clinical trial. METHODS: Dogs received toceranib at 2.75 mg/kg once every other day. After 2 weeks, oral CYC was added at 15 mg/m(2) daily. Numbers of Treg and lymphocyte subsets were measured in blood by flow cytometry during the 8-week study period. Serum concentrations of IFN-γ were measured by ELISA. RESULTS: Administration of toceranib significantly decreased the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving toceranib and CYC demonstrated a significant increase in serum concentrations of IFN-γ, which was inversely correlated with Treg numbers after 6 weeks of combination treatment. CONCLUSIONS: In addition to antitumor effects, these data support further investigations into the immunomodulatory effects of toceranib, administered alone or in combination with CYC in dogs with cancer.
BACKGROUND: Tyrosine kinase inhibitors (TKIs) and metronomic dosing of cyclophosphamide (CYC) can improve tumor control by suppression of regulatory T cells (Treg) and restoration of T cell-mediated immune responses in mice and humans. The immunomodulatory effects of the TKI toceranib, as a single agent or in combination with metronomic CYC, have not been previously investigated in dogs. HYPOTHESIS: The primary objectives of this study were to determine the effects of toceranib and metronomic CYC treatment on lymphocyte subsets including Treg and on interferon-gamma (IFN-γ) secretion in dogs with cancer. We hypothesized that toceranib would selectively decrease Treg numbers and increase IFN-γ production and that addition of CYC would further enhance these effects. ANIMALS: Fifteen client-owned dogs with advanced tumors were entered into a prospective clinical trial. METHODS:Dogs received toceranib at 2.75 mg/kg once every other day. After 2 weeks, oral CYC was added at 15 mg/m(2) daily. Numbers of Treg and lymphocyte subsets were measured in blood by flow cytometry during the 8-week study period. Serum concentrations of IFN-γ were measured by ELISA. RESULTS: Administration of toceranib significantly decreased the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving toceranib and CYC demonstrated a significant increase in serum concentrations of IFN-γ, which was inversely correlated with Treg numbers after 6 weeks of combination treatment. CONCLUSIONS: In addition to antitumor effects, these data support further investigations into the immunomodulatory effects of toceranib, administered alone or in combination with CYC in dogs with cancer.
Authors: Alessandra Gavazza; George Lubas; Arthur Fridman; Daniela Peruzzi; Joseph A Impellizeri; Laura Luberto; Emanuele Marra; Giuseppe Roscilli; Gennaro Ciliberto; Luigi Aurisicchio Journal: Hum Gene Ther Date: 2013-08 Impact factor: 5.695
Authors: Kriston F Weaver; John V Stokes; Sagen A Gunnoe; Joyce S Follows; Lydia Shafer; Mais G Ammari; Todd M Archer; John M Thomason; Andrew J Mackin; Lesya M Pinchuk Journal: J Vet Med Res Date: 2014-06-09
Authors: Kayla Harding; Carlos H De Mello Souza; Keijiro Shiomitsu; Elizabeth Maxwell; Judit Bertran Journal: Can J Vet Res Date: 2021-10 Impact factor: 1.310
Authors: Matthew Sherger; William Kisseberth; Cheryl London; Susan Olivo-Marston; Tracey L Papenfuss Journal: BMC Vet Res Date: 2012-10-31 Impact factor: 2.741